Repertoire Immune Medicines Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
90
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$189M
- Investors
-
7
Repertoire Immune Medicines General Information
Description
Operator of a biotechnology company intended to unlock and direct the human immune system to prevent or treat cancer. The company offers a repertoire of T cell receptor (TCR)-antigen codes that drive health and disease and helps in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines, enabling clinicians to prevent or treat cancer, autoimmune disorders, infectious diseases, and other serious diseases among patients.
Contact Information
Website
www.repertoire.comCorporate Office
- One Kendall Square
- Building 1400W, 5th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- One Kendall Square
- Building 1400W, 5th Floor
- Cambridge, MA 02139
- United States
Repertoire Immune Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 13-Apr-2021 | $189M | Completed | Clinical Trials - General | ||
| 4. Later Stage VC | 25-Mar-2020 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 15-Jul-2019 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 18-Apr-2018 | $46M | $46M | Completed | Clinical Trials - General | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Clinical Trials - General |
Repertoire Immune Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 15,776,666 | $0.000100 | $1 | $1 | $1 | 22.65% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Repertoire Immune Medicines Comparisons
Industry
Financing
Details
Repertoire Immune Medicines Competitors (5)
One of Repertoire Immune Medicines’s 5 competitors is Conformation-X Therapeutics, a Venture Capital-Backed company based in Canton, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Conformation-X Therapeutics | Venture Capital-Backed | Canton, MA | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| BITT (Drug Discovery) | Venture Capital-Backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
Repertoire Immune Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Repertoire Immune Medicines Patents
Repertoire Immune Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4784158-A1 | Mhc-presentable peptides associated with type 1 diabetes | Pending | 29-Sep-2023 | ||
| WO-2025072849-A1 | Mhc-presentable peptides associated with type 1 diabetes | Inactive | 29-Sep-2023 | ||
| AU-2024309737-A1 | Lipid particles for delivering a payload | Pending | 29-Jun-2023 | ||
| EP-4734964-A1 | Lipid particles for delivering a payload | Pending | 29-Jun-2023 | ||
| WO-2025007024-A1 | Lipid particles for delivering a payload | Inactive | 29-Jun-2023 | A61K9/5031 |
Repertoire Immune Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Repertoire Immune Medicines Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alaska Permanent Fund | Sovereign Wealth Fund | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority | ||
| PSP Investments (Canada) | Limited Partner | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority | ||
| T1D Fund | Venture Capital | Minority |
Repertoire Immune Medicines Acquisitions (1)
Repertoire Immune Medicines’s most recent deal was a Merger/Acquisition with Tepthera. The deal was made on 01-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tepthera | 01-Nov-2022 | Merger/Acquisition | Drug Discovery |
Repertoire Immune Medicines FAQs
-
When was Repertoire Immune Medicines founded?
Repertoire Immune Medicines was founded in 2015.
-
Where is Repertoire Immune Medicines headquartered?
Repertoire Immune Medicines is headquartered in Cambridge, MA.
-
What is the size of Repertoire Immune Medicines?
Repertoire Immune Medicines has 90 total employees.
-
What industry is Repertoire Immune Medicines in?
Repertoire Immune Medicines’s primary industry is Drug Discovery.
-
Is Repertoire Immune Medicines a private or public company?
Repertoire Immune Medicines is a Private company.
-
What is Repertoire Immune Medicines’s current revenue?
The current revenue for Repertoire Immune Medicines is .
-
How much funding has Repertoire Immune Medicines raised over time?
Repertoire Immune Medicines has raised $273M.
-
Who are Repertoire Immune Medicines’s investors?
Alaska Permanent Fund, Invus (Private Equity), PSP Investments (Canada), SoftBank Investment Advisers, and T1D Fund are 5 of 7 investors who have invested in Repertoire Immune Medicines.
-
Who are Repertoire Immune Medicines’s competitors?
Conformation-X Therapeutics, Vedanta Biosciences, BITT (Drug Discovery), Kite Pharma, and Genetix Biotherapeutics are competitors of Repertoire Immune Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
